PAO Group Inc (PAOG)

[sam1933]

Via its recent acquisitions, PAOG has re-positioned itself as an emerging CBD Biopharma company on a development path to treat two major respiratory diseases that each represent billions in potential market sizes. PAOG also acquired a cannabis cultivation operation generating $300,000 in annual revenue.

Leveraging a series of favorable studies, the Company is set to engage a CRO to initiate the process for potential FDA approval of RespRx, its new flagship COPD treatment. COPD represents an estimated $14.1B market by 2025.

After completing a recent 25 patient study using RespRx to treat COVID-19 symptoms, PAOG is preparing to commence a similar development pathway for this disease. Management expects to soon file a CTAP (Coronavirus Treatment Acceleration Program) application and given the current pandemic, it is likely to be fast-tracked.

Now that the key acquisitions have been closed management is preparing to complete corporate, capital markets, and investor relations housekeeping tasks to ensure investors have access to the most recent company financial statements and reports.

As progress and milestones on the development path occur, PAOG’s shares warrant a closer look as they could serve as catalysts to drive the overall valuation higher for PAOG’s shares.

see more: https://www.goldmanresearch.com/202008131283/Opportunity-Research/under-the-radar-cbd-pharma-player-could-offer-major-upside.html